心血管疾病中的内皮祖细胞：从生物标志物到治疗剂
Endothelial progenitor cells in cardiovascular diseases: from biomarker to therapeutic agent.
作者信息
Liu Hui-Bin, Gong Yuan-Feng, Yu Chang-Jiang, Sun Ying-Ying, Li Xin-Yuan, Zhao Dan, Zhang Zhi-Ren
机构信息
Departments of Clinical Pharmacy and Cardiology, the 2nd Affiliated Hospital, Harbin Medical University, The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, 150086 P.R. China.
出版信息
Regen Med Res. 2013 Dec 6;1(1):9. doi: 10.1186/2050-490X-1-9. eCollection 2013 Dec.
Regenerative medicine techniques to recover cardiac and vascular function are being increasingly investigated as management strategies for cardiovascular diseases. Circulating endothelial progenitor cells (EPCs) derived from bone marrow are immature cells capable of differentiating into mature endothelial cells and play a role in vascular reparative processes and neoangiogenesis. The potency of EPCs for cardiovascular regeneration has been demonstrated in many preclinical studies and therapeutic utility of EPCs has been evaluated in early-phase clinical trials. However, the regenerative activity and efficiency of the differentiation of EPCs are still limited, and a directed differentiation method for EPCs cells has not been fully demonstrated. In this review, we introduce the role of circulating EPCs as biomarkers of cardiovascular diseases and medical applications of EPCs for cardiovascular regeneration.
作为心血管疾病的管理策略，恢复心脏和血管功能的再生医学技术正受到越来越多的研究。源自骨髓的循环内皮祖细胞（EPCs）是能够分化为成熟内皮细胞的未成熟细胞，在血管修复过程和新生血管形成中发挥作用。EPCs在心血管再生方面的潜力已在许多临床前研究中得到证实，并且EPCs的治疗效用已在早期临床试验中得到评估。然而，EPCs的再生活性和分化效率仍然有限，并且尚未充分证明EPCs细胞的定向分化方法。在本综述中，我们介绍了循环EPCs作为心血管疾病生物标志物的作用以及EPCs在心血管再生中的医学应用。
Zotero 插件